This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Adrenal gland (controls excluding all cancers)
CD2_BENIGN_ADRENAL_EXALLC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
D35.0&
Hospital discharge: ICD-9
2270
Hospital discharge: ICD-8
2260
Cause of death: ICD-10
D35.0&
Cause of death: ICD-9
2270
Cause of death: ICD-8
2260
2 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints None
-
Remove individuals based on genotype QC
1959
CD2_BENIGN_ADRENAL_EXALLC
Control definitions
Control exclude
C3_CANCER
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D35
Name in latin
Neoplasma benignum glandulae suprarenalis
No upset plot: script not run.
No upset table: script not run.
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Adrenal gland (controls excluding all cancers)
based on the number of shared cases.
Broader endpoints:
- Benign neoplasm: Adrenal gland
- Benign neoplasm of other and unspecified endocrine glands
- Benign neoplasm of other and unspecified endocrine glands (controls excluding all cancers)
- Benign neoplasms
- Benign neoplasms (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1959 | 1140 | 819 |
| Unadjusted prevalence (%) | 0.48 | 0.50 | 0.45 |
| Mean age at first event (years) | 62.23 | 60.45 | 64.70 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_BENIGN_ADRENAL_EXALLC – Benign neoplasm: Adrenal gland (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Benign neoplasm: Adrenal gland (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.